Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 + Gemcitabine + Docetaxel in Leiomyosarcoma
NCT05712694Phase 3Terminated
- Sponsor
- Polaris Group
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of Pegargiminase in leiomyosarcoma (LMS), sponsored by Polaris Group. Started Nov 2023; status: terminated.
02
Drugs
Pegargiminase
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT05712694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712694.